PLUS THERAPEUTICS, Inc. (PSTV): Price and Financial Metrics
GET POWR RATINGS... FREE!
PSTV Stock Price Chart Interactive Chart >
PSTV Price/Volume Stats
Current price | $0.58 | 52-week high | $2.95 |
Prev. close | $0.56 | 52-week low | $0.41 |
Day low | $0.56 | Volume | 101,300 |
Day high | $0.60 | Avg. volume | 2,090,009 |
50-day MA | $0.77 | Dividend yield | N/A |
200-day MA | $1.28 | Market Cap | 12.77M |
PLUS THERAPEUTICS, Inc. (PSTV) Company Bio
PLUS THERAPEUTICS, Inc. is a clinical-stage pharmaceutical company. The Company discovers, develops, and commercializes specialty novel therapeutics for the treatment of cancer and other life-threatening diseases. PLUS THERAPEUTICS operates in the States of Texas and California.
Latest PSTV News From Around the Web
Below are the latest news stories about Plus Therapeutics Inc that investors may wish to consider to help them evaluate PSTV as an investment opportunity.
Plus Therapeutics, Inc. (PSTV) CEO Marc Hedrick on Q4 2021 Results - Earnings Call TranscriptPlus Therapeutics, Inc. (PSTV) Q4 2021 Earnings Conference Call February 24, 2022, 05:00 PM ET Company Participants Marc Hedrick - President & CEO Norman LaFrance - Chief Medical Officer Andrew Sims - CFO Conference Call Participants Jianing Li - Maxim Group Sean Lee - H.C. Wainwright Ed Woo - Ascendiant... |
Plus Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Business HighlightsExpanded pipeline with recently licensed targeted interventional radiotherapeutics platform Announced positive interim data from ReSPECT-GBM Phase 1 clinical trial Management to host conference call today at 5:00 p.m. ET AUSTIN, Texas, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced financial results for the f |
Plus Therapeutics Partners with Medidata to Apply Innovative Synthetic Control ArmⓇ Solution to Accelerate Brain Cancer Clinical TrialInitial plan to evaluate project feasibility, may lead to expanded partnership for clinical and regulatory implementationAUSTIN, Texas, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced a partnership with Medidata, a Dassault Systèmes company, to evaluate the use of its Synthetic Control Arm® (SCA) solution in a |
Plus Therapeutics to Announce Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call on February 24, 2022AUSTIN, Texas, Feb. 18, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult to treat cancers, announced that the Company will report fourth quarter and full year 2021 financial results on Thursday, February 24, 2022, after market close. Plus Therapeutics’ management team will then host a conference call and webcast at 5:00 p.m. ET to discuss the financial |
Plus Therapeutics to Present at BIO CEO & Investor ConferenceAUSTIN, Texas, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced that Marc H. Hedrick M.D., President and Chief Executive Officer of Plus Therapeutics, will present a company overview during the BIO CEO & Investor Conference on Monday, February 14, 2022 at 1:15 p.m. ET, at the New York Marriott Marquis. The Comp |
PSTV Price Returns
1-mo | -15.09% |
3-mo | -43.69% |
6-mo | -61.33% |
1-year | -75.53% |
3-year | -95.45% |
5-year | -99.89% |
YTD | -44.76% |
2021 | -48.02% |
2020 | -15.83% |
2019 | -83.45% |
2018 | -90.33% |
2017 | -80.13% |
Loading social stream, please wait...